Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of Cabozantinib (XL184) in Adults With Advanced Malignancies

This study has been completed.
Information provided by (Responsible Party):
Exelixis Identifier:
First received: July 12, 2009
Last updated: February 18, 2015
Last verified: February 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2014
  Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by Identifier (NCT Number):